Ahmed Bahi on Lina Merghani’s Critique of Early Withdrawal of Aspirin after PCI
Ahmed Bahi, Critical Care Pharmacist Specialist in Trauma Services at Hamad Medical Corporation, shared on LinkedIn:
”Exciting News in Cardiovascular Research!
I’m thrilled to share that I recently had the opportunity to supervise my pharmD student Lina Merghani in critique of a groundbreaking study published in NEJM focused on the ”early withdrawal of aspirin after percutaneous coronary intervention (PCI) in acute acute coronary syndrome (ACS)”..
In my critique, Dr Lina highlighted benefit vs risk of stopping aspiring after acute ACS.
I want to commend our PharmD student for their hard work and dedication to advancing care for trauma patients.
Your contributions are paving the way for improved patient outcomes.
Let’s continue to push the boundaries of knowledge and improve the lives of our patients.”
Read the full article in NEJM.
Article: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes
Authors: NEO-MINDSET Trial Investigators
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 23:18Claire Hills: New Paper on Immune Surveillance and Immune Evasion of Senescent Cells
-
Aug 14, 2026, 23:16Are We Overlooking What Matters Most to Women with Von Willebrand Disease? – RPTH Journal
-
Aug 14, 2026, 23:15Markus Müller: A New Base Editing Approach Targeting PCSK9 to Lower Cholesterol Levels
-
Aug 14, 2026, 23:14Chokri Ben Lamine: Avatrombopag in Hematology – Dosing and Monitoring
-
Aug 14, 2026, 23:13Bianca Rocca: PRECISE-DAPT Score Identifies Bleeding Risk After CABG in Patients With POAF
-
Aug 14, 2026, 19:04Ravi Kumar: Why Lupus Anticoagulant Predicts Clots, Not Bleeding
-
Aug 14, 2026, 18:53Veli Bakalov: The Number Every Hematologist Should Know in Polycythemia Vera
-
Aug 14, 2026, 18:41Marta Velia Antonini: Can Nitric Oxide Protect the ECMO Circuit Without Systemic Anticoagulation?
-
Aug 14, 2026, 18:30Irina Gontschar: What the Epkinly FDA Review Teaches Us About Sponsor Oversight